Literature DB >> 29234136

Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury.

Sandra Carvalho1,2, Jorge Leite1,2,3, Felipe Jones1, Leslie R Morse4,5,6, Ross Zafonte4,7, Felipe Fregni8,9.   

Abstract

STUDY
DESIGN: Secondary analysis of a clinical trial.
OBJECTIVES: To analyze adherence to 1-year transcranial Direct Current Stimulation (tDCS) clinical trial in people with chronic pain due to spinal cord injury (SCI). We also explore the association between dropout and several baseline variables such as age, depression levels, pain severity, number of days with pain in the last 7 days, walking ability, sleep, work, relationship with others, and enjoyment with life.
SETTING: Boston, USA.
METHODS: Forty-six participants were enrolled in this trial, and 33 participants were randomized to receive either active or sham tDCS.
RESULTS: Using the full intention-to-treat (ITT) criteria, only 8 participants (24%) finished the study. The median time to dropout was seven (IQR:6,19) sessions (i.e., immediately after the first follow-up), regardless of the type of stimulation that participants received (active vs. sham tDCS) (χ2 = 0.025, p = 0.875). An exploratory analysis suggested that only the number of days with pain in the last 7 days was moderately associated with dropout, with people experiencing less pain being more prone to dropout from the study.
CONCLUSIONS: Despite all the measures to improve study adherence (such as providing parking, flexibility to schedule sessions, follow-up with participants by phone), it seems that long follow-up periods may increase the likelihood of dropout. Given the need to understand long-term effects of interventions, longitudinal trials need to consider alternative designs or methods of treatment (for instance home treatment or home assessment) to decrease attrition rate.

Entities:  

Mesh:

Year:  2017        PMID: 29234136     DOI: 10.1038/s41393-017-0023-5

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  29 in total

1.  Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level.

Authors:  Benedikt Brommer; Odilo Engel; Marcel A Kopp; Ralf Watzlawick; Susanne Müller; Harald Prüss; Yuying Chen; Michael J DeVivo; Felix W Finkenstaedt; Ulrich Dirnagl; Thomas Liebscher; Andreas Meisel; Jan M Schwab
Journal:  Brain       Date:  2016-01-10       Impact factor: 13.501

2.  A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury.

Authors:  Felipe Fregni; Paulo S Boggio; Moises C Lima; Merari J L Ferreira; Tim Wagner; Sergio P Rigonatti; Anita W Castro; Daniel R Souza; Marcelo Riberto; Steven D Freedman; Michael A Nitsche; Alvaro Pascual-Leone
Journal:  Pain       Date:  2006-03-27       Impact factor: 6.961

3.  Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans.

Authors:  M A Nitsche; W Paulus
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

4.  Pain severity and mobility one year after spinal cord injury: a multicenter, cross-sectional study.

Authors:  Bianca F Marcondes; Shruti Sreepathi; Justin Markowski; Dung Nguyen; Shannon R Stock; Sandra Carvalho; Denise Tate; Ross Zafonte; Leslie R Morse; Felipe Fregni
Journal:  Eur J Phys Rehabil Med       Date:  2015-11-27       Impact factor: 2.874

5.  Long-Lasting Effect of Transcranial Direct Current Stimulation in the Reversal of Hyperalgesia and Cytokine Alterations Induced by the Neuropathic Pain Model.

Authors:  Stefania Giotti Cioato; Liciane Fernandes Medeiros; Paulo Ricardo Marques Filho; Rafael Vercelino; Andressa de Souza; Vanessa Leal Scarabelot; Carla de Oliveira; Lauren Naomi Spezia Adachi; Felipe Fregni; Wolnei Caumo; Iraci L S Torres
Journal:  Brain Stimul       Date:  2015-12-15       Impact factor: 8.955

6.  A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury.

Authors:  Philip J Siddall; Joan M McClelland; Susan B Rutkowski; Michael J Cousins
Journal:  Pain       Date:  2003-06       Impact factor: 6.961

Review 7.  Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.

Authors:  Elke Vervölgyi; Mandy Kromp; Guido Skipka; Ralf Bender; Thomas Kaiser
Journal:  BMC Med Res Methodol       Date:  2011-09-21       Impact factor: 4.615

8.  Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients.

Authors:  Karel Kostev; Juliana Rex; Thilo Eith; Christina Heilmaier
Journal:  Ger Med Sci       Date:  2014-10-16

9.  Clinically Effective Treatment of Fibromyalgia Pain With High-Definition Transcranial Direct Current Stimulation: Phase II Open-Label Dose Optimization.

Authors:  Laura Castillo-Saavedra; Nigel Gebodh; Marom Bikson; Camilo Diaz-Cruz; Rivail Brandao; Livia Coutinho; Dennis Truong; Abhishek Datta; Revital Shani-Hershkovich; Michal Weiss; Ilan Laufer; Amit Reches; Ziv Peremen; Amir Geva; Lucas C Parra; Felipe Fregni
Journal:  J Pain       Date:  2015-10-09       Impact factor: 5.820

10.  Neuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial.

Authors:  Aline P Brietzke; Joanna R Rozisky; Jairo A Dussan-Sarria; Alicia Deitos; Gabriela Laste; Priscila F T Hoppe; Suzana Muller; Iraci L S Torres; Mário R Alvares-da-Silva; Rivadavio F B de Amorim; Felipe Fregni; Wolnei Caumo
Journal:  Front Neurosci       Date:  2016-01-11       Impact factor: 4.677

View more
  4 in total

1.  Feasibility of remotely-supervised tDCS in a person with neuropathic pain due to spinal cord injury.

Authors:  Sandra Carvalho; Jorge Leite; Camila B Pinto; Leslie R Morse; Ross Zafonte; Felipe Fregni
Journal:  J Spinal Cord Med       Date:  2018-03-28       Impact factor: 1.985

2.  The pros and cons of tDCS as a therapeutic tool in the rehabilitation of chronic pain.

Authors:  J S Ho; E Slawka; K Pacheco-Barrios; A Cardenas-Rojas; L Castelo-Branco; F Fregni
Journal:  Princ Pract Clin Res       Date:  2022-07-03

3.  Recruitment characteristics and non-adherence associated factors of fibromyalgia patients in a randomized clinical trial: A retrospective survival analysis.

Authors:  Alejandra Cardenas-Rojas; Luis Castelo-Branco; Kevin Pacheco-Barrios; Emad Salman Shaikh; Elif Uygur-Kucukseymen; Stefano Giannoni-Luza; Luna Vasconcelos Felippe; Paola Gonzalez-Mego; Maria Alejandra Luna-Cuadros; Anna Carolyna Lepesteur Gianlorenco; Paulo E P Teixeira; Wolnei Caumo; Felipe Fregni
Journal:  Contemp Clin Trials Commun       Date:  2021-11-17

Review 4.  Methods and strategies of tDCS for the treatment of pain: current status and future directions.

Authors:  Kevin Pacheco-Barrios; Alejandra Cardenas-Rojas; Aurore Thibaut; Beatriz Costa; Isadora Ferreira; Wolnei Caumo; Felipe Fregni
Journal:  Expert Rev Med Devices       Date:  2020-09-15       Impact factor: 3.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.